bioMérieux – First-Quarter 2018 Business Review19 April, 2018
- Strong sales dynamic in first-quarter 2018, with sales up 12.5% at constant exchange rates and scope of consolidation:
- €587 million in sales
- Up 3.4% as reported
- Growth driven by molecular biology in the context of an intense flu season in the United States, and by buoyant business in the Asia-Pacific region
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In the first quarter, bioMérieux delivered a sound commercial performance. The recent acquisition of Astute Medical will strengthen bioMérieux’s commitment and position in immunoassays and is a perfect fit with our strategy of developing high medical value tests in order to improve patient care.”
Marcy l’Étoile (France), April 19, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2018.
Consolidated sales rose to €587 million in the first quarter of 2018, up from €568 million in the yearearlier
period. Sales advanced 12.5% at constant exchange rates and scope of consolidation. On a reported basis in euros, sales moved up 3.4% year-on-year, hit as anticipated by a negative currency impact of €52 million resulting from the appreciation in the euro against a number of currencies, notably the U.S. dollar.
bioMérieux Sweden AB - Hantverksvägen 15 - SE-436 33 Askim, SWEDEN